Koninklijke Philips (PHIA) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
3 Feb, 2026Opening remarks and agenda
The meeting opened with introductions of the Board, Executive Committee, and external auditor, emphasizing the importance of the AGM and shareholder engagement.
The agenda included financial performance, dividend policy, remuneration, board appointments, and sustainability.
Financial performance review
2024 saw solid progress in innovation and profitability, despite global uncertainties and slower growth.
Orders and sales grew, but demand in China declined due to subdued consumer confidence and longer procurement cycles.
Strong profitability improvement and cash flow were achieved, with a strengthened balance sheet.
The company adjusted growth expectations for 2024 and prioritized profitable growth for 2025.
Board and executive committee updates
New appointments included a CFO and several Executive Committee members, achieving gender parity.
Proposals were made to appoint Bob White to the Supervisory Board and reappoint Indra Nooyi, Chua Sock Koong, and Marnix van Ginneken.
David Pyott was thanked for his service as Chair of the Quality and Regulatory Committee.
Latest events from Koninklijke Philips
- Targeting mid-single-digit sales growth and mid-teens margin by 2028 through innovation and execution.PHIA
CMD 202610 Feb 2026 - Strong 2025 growth and margin gains set up for higher sales and profitability in 2026.PHIA
Q4 202510 Feb 2026 - Q2 saw 2% sales growth, 9% order intake rise, margin gains, and major Respironics settlements.PHIA
Q2 20242 Feb 2026 - AI-driven health innovation and open platforms fuel growth and ESG leadership.PHIA
Show & Tell 202420 Jan 2026 - Strong margin gains offset flat sales and China weakness, with robust operational performance.PHIA
Q3 202418 Jan 2026 - 2024 saw margin gains, strong cash flow, and finalized US Respironics settlements despite China declines.PHIA
Q4 20248 Jan 2026 - Sales fell 2% but order intake and net income improved; margin guidance cut on tariffs.PHIA
Q1 202524 Nov 2025 - Margin up 130 bps to 12.4% on 1% sales growth and strong order intake; guidance raised.PHIA
Q2 20255 Nov 2025 - Q3 2025 saw 8% order growth, 3% sales growth, and margin expansion, with strong cash flow.PHIA
Q3 20254 Nov 2025